On August 3, UFP Technologies (NASDAQ:UFPT) reported second-quarter net income of $20.9 million, up 21.4% from $17.2 million a year earlier, alongside net sales of $174.0 million, a 15.1% jump from $151.2 million. Both figures, along with adjusted earnings per share of $2.92, marked the best quarter in the company's history. For the six months ended June 30, net income reached $38.3 million on sales of $328.2 million, up from $34.4 million and $299.3 million, respectively, in the same period of 2025. The headline numbers look clean. What sits underneath them is less tidy.
The quarter's strength did not come from one customer or one product line carrying the rest. UFP Technologies' top five customers grew 14.7%, and the remainder of its MedTech business grew even faster, at 19.7%. Organic sales growth, stripping out acquisitions, still ran at 12.4% for the quarter and 6.8% for the first half, which means the base business is expanding on its own rather than relying on deals to pad the numbers. Gross margin climbed to 29.3% from 28.8% a year earlier, and operating income rose 15.5% to $28.1 million, outpacing revenue growth. Adjusted EBITDA followed the same pattern, up 14.3% to $36.4 million for the quarter.
The balance sheet moved in a healthy direction too. Long-term debt, excluding current installments, fell to $104.8 million from $122.9 million at the end of 2025, while total equity grew to $462.4 million from $423.9 million over the same stretch. UFP Technologies also added executives in business development, operations, and legal during the quarter, a sign that management is building out the organization to support the growth it is already seeing rather than reacting to it after the fact.
The same earnings release that touted record results also flagged where the strain is showing. CEO Mitch Rock said the company's ongoing investment in its Dominican Republic operations is "taking longer than anticipated" to pay off and is creating "near-term mix and margin pressure" within the U.S. business. That is a direct admission that the expansion driving future capacity is costing money today. Selling, general and administrative expenses grew 21.8% to $22.8 million, faster than the 15.1% sales growth, pushing SG&A as a percentage of sales up to 13.1% from 12.4%. On an adjusted basis, SG&A crept up to 11.7% of sales from 10.8%.
Not every part of the business is contributing to the growth story either. While MedTech surged, the non-medical segment was flat for the quarter, leaving the entire growth burden on one part of the portfolio. Cash on hand also dropped sharply, falling to $9.0 million from $20.3 million at the end of 2025, even as receivables grew to $113.2 million from $82.9 million and inventories rose to $100.1 million from $86.9 million, a combination that suggests working capital is absorbing more cash than it used to.
#sales
The quarter's strength did not come from one customer or one product line carrying the rest. UFP Technologies' top five customers grew 14.7%, and the remainder of its MedTech business grew even faster, at 19.7%. Organic sales growth, stripping out acquisitions, still ran at 12.4% for the quarter and 6.8% for the first half, which means the base business is expanding on its own rather than relying on deals to pad the numbers. Gross margin climbed to 29.3% from 28.8% a year earlier, and operating income rose 15.5% to $28.1 million, outpacing revenue growth. Adjusted EBITDA followed the same pattern, up 14.3% to $36.4 million for the quarter.
The balance sheet moved in a healthy direction too. Long-term debt, excluding current installments, fell to $104.8 million from $122.9 million at the end of 2025, while total equity grew to $462.4 million from $423.9 million over the same stretch. UFP Technologies also added executives in business development, operations, and legal during the quarter, a sign that management is building out the organization to support the growth it is already seeing rather than reacting to it after the fact.
The same earnings release that touted record results also flagged where the strain is showing. CEO Mitch Rock said the company's ongoing investment in its Dominican Republic operations is "taking longer than anticipated" to pay off and is creating "near-term mix and margin pressure" within the U.S. business. That is a direct admission that the expansion driving future capacity is costing money today. Selling, general and administrative expenses grew 21.8% to $22.8 million, faster than the 15.1% sales growth, pushing SG&A as a percentage of sales up to 13.1% from 12.4%. On an adjusted basis, SG&A crept up to 11.7% of sales from 10.8%.
Not every part of the business is contributing to the growth story either. While MedTech surged, the non-medical segment was flat for the quarter, leaving the entire growth burden on one part of the portfolio. Cash on hand also dropped sharply, falling to $9.0 million from $20.3 million at the end of 2025, even as receivables grew to $113.2 million from $82.9 million and inventories rose to $100.1 million from $86.9 million, a combination that suggests working capital is absorbing more cash than it used to.
#sales
6 days ago
